Japan Patent Office Licenses GeneCards(R) from Xe...(proprietary successfully overcoming barr...)

Date:5/5/2008

proprietary, successfully overcoming barriers of data format heterogeneity. GeneCards is unique in its combination of user-friendly interface, as well as the organization and display of just the right mix of links and detailed information. Data are divided into "fields" such as "Aliases," "Location," "Ontologies," "Expression" and "SNPs," all searchable by keywords. Since GeneCards employs automatic data mining from dozens of sources, it provides a truly complete summary for each gene. GeneCards(R) (http://www.genecards.org) was developed over the last 10 years by a world-leading bioinformatics team at the Weizmann Institute of Science in Israel.

About Xennex

Xennex, Inc. (http://www.xennexinc.com) is a dynamic privately held company that is dedicated to providing Biotechnology, Pharmaceutical and other life sciences companies, as well as organizations dealing with biotechnology intellectual property, the highest level of services and tools to enhance their gene-based research. Xennex' products help such organizations to optimize their efforts to develop innovative medical products and services. Xennex operations worldwide are carried out from its offices in Massachusetts, USA.

Xennex' customers include many of the world leading biotech and pharmaceutical companies and organizations dealing with intellectual property, located in North America, Europe and Japan. Xennex' products are used in hundreds of commercial and academic organizations by thousands of users around the globe.

About Bioscene

Bioscene Informatics Inc. (http://www.bioscene.co.jp) is a privately held Japanese company dedicated to providing life science professionals useful tools to help them work smarter. In addition to developing its own products, Bioscene assists a selection of Western companies with their
'/>"/>

SOURCE Xennex, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
2. Exclusive Rights to Kuvan(TM) Data Licensed to Asubio Pharma in Japan
3. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
6. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
7. NPS Pharmaceuticals Announces Approval of Cinacalcet HCl in Japan
8. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
9. Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan
10. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
11. American Scientists Named as Laureates of the 2008 (24th) Japan Prize